AstraZeneca, Daiichi Sankyo’s Enhertu claims another Phase 3 victory in HER2-low breast cancer

Enhertu notched another win for AstraZeneca and Daiichi Sankyo that could see uptake moved slightly earlier in a specific subset of breast cancer patients.

The Phase 3 DESTINY-Breast06 study set Enhertu against chemotherapy. The ADC hit the progression-free survival primary endpoint in the primary trial population of HR-positive breast cancer patients who are low on HER2, or the human epidermal growth factor receptor 2, and have gone through one or more lines of endocrine therapy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Does Ozempic increase the risk of suicidal thoughts? A new study muddles the picture

A new observational study found that people taking Ozempic and Wegovy appeared to experience suicidal thoughts at a higher rate than people on other drugs,

August 20, 2024

Opinion | Fighting Blind: There Remains Much We Don’t Know About the H5N1 Outbreak

Adalja is a practicing infectious disease, critical care, and emergency physician. For approximately the past year, the ongoing influenza A H5N1 clade 2.3.4.4b outbreak has

August 2, 2024

Exploring how diets rich in saturated fats and cholesterol influence periodontal diseases

In a research, led by the University of Granada, in which researchers from the Universidad Europea del Atlántico (European University of the Atlantic, UNEATLANTICO), such

February 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.